Document Detail

(18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer.
MedLine Citation:
PMID:  20217449     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The objectives of this study were to reveal the utility of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) within 7 days after chemoradiotherapy to predict prognosis in patients with postoperative recurrent esophageal cancer.
MATERIALS AND METHODS: Patients scheduled to undergo concurrent chemoradiotherapy for postoperative locoregional recurrence of esophageal cancer were recruited. Selection criteria were: (1) locoregional recurrence, (2) no previous radiation therapy, (3) planning treatment with concurrent chemoradiotherapy, (4) FDG-PET performed <2 weeks before chemoradiotherapy, and (5) no serious diabetes. FDG-PET was performed <7 days after chemoradiotherapy. No more treatment after chemoradiotherapy was given until disease progression was diagnosed according to the Response Evaluation Criteria in Solid Tumors (RECIST). Correlations of FDG-PET findings with cause-specific survival and local control rates were investigated prospectively.
RESULTS: Twenty patients were enrolled. Median observation period of patients who survived was 45.0 months. Median maximum standardized uptake value (SUV(max)) after chemoradiotherapy was 2.4, and median SUV(max) before chemoradiotherapy was 8.4. Cause-specific survival and local control rates were significantly better for patients with SUV(max) < or = 2.4 after chemoradiotherapy (log-rank test, P = 0.033 and 0.010, respectively). SUV(max) before chemoradiotherapy tended to be correlated only with cause-specific survival rate (log-rank test, P = 0.076). Change in metabolic activity of FDG was significantly correlated with local control rate (log-rank test, P = 0.042).
CONCLUSIONS: FDG-PET performed even <7 days after chemoradiotherapy predicts prognosis in patients with postoperative recurrent esophageal cancer.
Keiichi Jingu; Tomohiro Kaneta; Kenji Nemoto; Ken Takeda; Yoshihiro Ogawa; Hisanori Ariga; Masashi Koto; Toru Sakayauchi; Yoshihiro Takai; Shoki Takahashi; Shogo Yamada
Related Documents :
20215979 - Fdg pet-ct in cervical cancer: relationship between primary tumor fdg uptake and metast...
20175199 - Effects of upstaging from pet scan on survival in head and neck squamous cell carcinoma.
20422889 - Fdg-pet positive granuloma of the liver mimicking local recurrence after hepatic resect...
17428249 - 18f-choline and/or 11c-acetate positron emission tomography: detection of residual or p...
3744679 - Psychosocial variables associated with the exceptional survival of patients with advanc...
16043319 - Maxillary sinus carcinoma: the only symptom was neck lymph node swelling.
18046259 - Are stage iv vestibular schwannomas preoperatively different from other stages?
17229769 - A double-blind placebo-controlled randomized study of chinese herbal medicine as comple...
2444439 - Speed of response to platinum-based chemotherapy: implications for the management of ep...
Publication Detail:
Type:  Journal Article     Date:  2010-03-10
Journal Detail:
Title:  International journal of clinical oncology     Volume:  15     ISSN:  1437-7772     ISO Abbreviation:  Int. J. Clin. Oncol.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-12     Completed Date:  2010-07-06     Revised Date:  2012-12-13    
Medline Journal Info:
Nlm Unique ID:  9616295     Medline TA:  Int J Clin Oncol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  184-90     Citation Subset:  IM    
Department of Radiation Oncology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Chemotherapy, Adjuvant
Esophageal Neoplasms / mortality,  radionuclide imaging*,  secondary,  therapy*
Fluorodeoxyglucose F18 / diagnostic use*
Kaplan-Meier Estimate
Lymphatic Metastasis
Middle Aged
Neoplasm Recurrence, Local*
Positron-Emission Tomography*
Predictive Value of Tests
Prospective Studies
Radiopharmaceuticals / diagnostic use*
Radiotherapy, Adjuvant
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient ...
Next Document:  A case of rapidly growing pulmonary carcinosarcoma.